Does TRICARE cover GLP-1 medications?

It can, and what decides it is the indication rather than the drug. For type 2 diabetes, GLP-1s such as Ozempic and Mounjaro are generally covered subject to formulary placement and prior authorization. For weight management, coverage of Wegovy and Zepbound is more restricted and carries its own criteria. Because TRICARE uses a formulary that changes, the only reliable answer for your situation comes from the TRICARE Formulary Search Tool plus a call — this page tells you what to look for and what to ask.

No, and this is the single most important thing on this page. TRICARE is a federal healthcare program, and federal anti-kickback law (42 U.S.C. § 1320a-7b) bars manufacturers from paying down copays for anyone enrolled in one. Every GLP-1 savings card says so in its own terms. No pharmacist can override it. People enrol online, assume the discount applies, and find out at the counter — your levers are your TRICARE copay, a prior authorization or appeal, and the manufacturer cash and patient-assistance programs, which are separate and do not carry the same restriction.

It depends on the formulary tier and where you fill it. TRICARE pharmacy copays differ substantially between a military treatment facility pharmacy, TRICARE home delivery, a network retail pharmacy and a non-network one — and the gap between them is often larger than any discount you could chase elsewhere. Home delivery is frequently the lowest-cost option for an ongoing medication. Check your specific tier and the current copay schedule before assuming.

Commonly, yes — particularly for weight-management use. A prior authorization asks your prescriber to document that you meet the criteria, which typically means the diagnosis, relevant clinical measures, and often what was tried before. Your prescriber files it. The most common reason a first attempt fails is missing documentation rather than genuine ineligibility, so it is worth confirming the chart actually contains the baseline figures before submission.

Yes, because they are approved for different things. Ozempic and Mounjaro are FDA-approved for type 2 diabetes; Wegovy and Zepbound for chronic weight management. Weight-management coverage is generally the more restricted category across payers. Both weight brands also carry a second, non-weight indication — Wegovy for cardiovascular risk reduction in adults with established heart disease plus overweight or obesity, and Zepbound for moderate-to-severe obstructive sleep apnea in obesity — and those are separate clinical routes rather than weight-loss requests.

First read the denial to find out which kind it is, because that decides whether appealing is worth your effort. A denial for unmet criteria or missing documentation is arguable and frequently reversed — those are usually paperwork problems. A denial because the drug is not on the formulary is a different fight, usually needing a medical-necessity exception rather than a standard appeal. TRICARE publishes its appeal process and deadlines; follow those specifically rather than generic insurance advice, because TRICARE is not an ACA-regulated commercial plan.

Price the covered route first — a copay usually beats every cash option. If you do end up paying cash, the manufacturer self-pay programs are the realistic figures: Zepbound from $299/mo (2.5 mg), Wegovy about $349/month at maintenance, and the oral Wegovy pill from around $149. Those cash programs are open to you; only the copay CARD is not.